v3.25.4
License and Collaboration Agreements (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Jan. 31, 2021
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Specified royalty term   10 years    
Maximum additional milestone payments   $ 1,522.0    
GSK | Niraparib        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Sales-based milestone payment       $ 12.0
Maximum additional milestone payments   16.0    
Argenx | Efgartigimod        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum additional milestone payments   42.5    
Issuance of ordinary shares in connection with collaboration and license arrangement (in shares) 5,681,820      
Upfront payment $ 62.3      
Novo Holdings | Omadacycline        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum additional milestone payments   40.5    
NovoCure | Tumor Treating Fields        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum additional milestone payments   68.0    
Deciphera | Ripretinib        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum additional milestone payments   160.0    
Innoviva | SUL-DUR        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum additional milestone payments   78.0    
Milestone payment     $ 8.0 3.0
BMS | Repotrectinib        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum additional milestone payments   111.0    
Milestone payment   5.0 25.0 5.0
BMS | Xanomeline and Trospium Chloride        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum additional milestone payments   117.0    
Milestone payment   15.0 $ 10.0  
Pfizer | Tisotumab Vedotin        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum additional milestone payments   258.0    
MediLink Therapeutics | DLL3 ADC        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum additional milestone payments   $ 592.0    
Upfront payment       $ 10.0